In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Hao, Jingli ^a,b   Madigan, Michele C ^c,d   Khatri, Aparajita ^a   Power, Carl A ^c   Hung, Tzong Tyng ^a,c   Beretov, Julia ^a,b   Chang, Lei ^a,b   Xiao, Weiwei ^a,b   Cozzi, Paul J ^a,b   Graham, Peter H ^a,b   Kearsley, John H ^a,b   Li, Yong ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD147 ANTIGEN; DOCETAXEL; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCARBOXYLATE TRANSPORTER 4; MULTIDRUG RESISTANCE PROTEIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENICITY; CELL GROWTH; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD147; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; MONOCARBOXYLIC ACID TRANSPORTERS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUSCLE PROTEINS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864536251     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040716     Document Type: Article

References (62)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. ((2008)) Cancer statistics, 2008. CA Cancer J Clin 58:: 71--96.
2. Chang SS, Kibel AS, ((2009)) The role of systemic cytotoxic therapy for prostate cancer. BJU Int 103:: 8--17.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. ((2004)) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 35:: 1502--1512.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, et al. ((2004)) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:: 1513--1520.
5. Calabro F, Sternberg CN, ((2007)) Current indications for chemotherapy in prostate cancer patients. Eur Urol 51:: 17--26.
6. Petrylak DP, ((2005)) Future directions in the treatment of androgen-independent prostate cancer. Urology 65:: 8--12.
7. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV, ((2008)) Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18:: 260--267.
8. Ponta H, Sherman L, Herrlich PA, ((2003)) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:: 33--45.
9. Bourguignon LY, Peyrollier K, Xia W, Gilad E, ((2008)) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283:: 17635--17651.
10. Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y, ((2010)) CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer. Curr Cancer Drug Targets 10:: 287--306.
11. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, et al. ((2011)) CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 121:: 1064--1074.
12. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, et al. ((2009)) Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 26:: 433--446.
13. Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, et al. ((2007)) Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene 26:: 836--850.
14. Benitez A, Yates TJ, Lopez LE, Cerwinka WH, Bakkar A, et al. ((2011)) Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res 71:: 4085--4095.
15. Gao AC, Lou W, Sleeman JP, Isaacs JT, ((1998)) Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res 58:: 2350--2352.
16. Omara-Opyene AL, Qiu J, Shah GV, Iczkowski KA, ((2004)) Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 84:: 894--907.
17. Yang K, Tang Y, Habermehl GK, Iczkowski KA, ((2010)) Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity. BMC Cancer 10:: 16.
18. Yan L, Zucker S, Toole BP, ((2005)) Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93:: 199--204.
19. Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, et al. ((2002)) Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 20:: 387--392.
20. Zhong WD, Liang YX, Lin SX, Li L, He HC, et al. ((2011)) Expression of CD147 is associated with prostate cancer progression. Int J Cancer 130:: 300--308.
21. Madigan MC, Kingsley EA, Cozzi PJ, Delprado WJ, Russell PJ, et al. ((2008)) The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother 57:: 1367--1379.
22. Qin XF, An DS, Chen IS, Baltimore D, ((2003)) Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 100:: 183--188.
23. Chen H, Hao J, Wang L, Li Y, ((2009)) Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101:: 432--440.
24. Hao J, Chen H, Madigan MC, Cozzi PJ, Beretov J, et al. ((2010)) Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer 103:: 1008--1018.
25. Wang L, Chen H, Liu F, Madigan MC, Power CA, et al. ((2011)) Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Lett 300:: 122--133.
26. Li Y, Rizvi SM, Ranson M, Allen BJ, ((2002)) 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. Br J Cancer 86:: 1197--1203.
27. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW, ((1991)) Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51:: 3753--3761.
28. Wang L, Chen H, Pourgholami MH, Beretov J, Hao J, et al. ((2011)) Anti-MUC1 Monoclonal Antibody (C595) and Docetaxel Markedly Reduce Tumor Burden and Ascites, and Prolong Survival in an in vivo Ovarian Cancer Model. PLoS One 6:: e24405.
29. Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, et al. ((2005)) MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 22:: 565--573.
30. Slomiany MG, Grass GD, Robertson AD, Yang XY, Maria BL, et al. ((2009)) Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res 69:: 1293--1301.
31. Slomiany MG, Dai L, Tolliver LB, Grass GD, Zeng Y, et al. ((2009)) Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides. Clin Cancer Res 15:: 7593--7601.
32. Toole BP, Slomiany MG, ((2008)) Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat 11:: 110--121.
33. Marieb EA, Zoltan-Jones A, Li R, Misra S, Ghatak S, et al. ((2004)) Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res 64:: 1229--1232.
34. Gilg AG, Tye SL, Tolliver LB, Wheeler WG, Visconti RP, et al. ((2008)) Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors. Clin Cancer Res 14:: 1804--1813.
35. Misra S, Ghatak S, Toole BP, ((2005)) Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 280:: 20310--20315.
36. Misra S, Ghatak S, Zoltan-Jones A, Toole BP, ((2003)) Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 278:: 25285--25288.
37. Wang WJ, Li QQ, Xu JD, Cao XX, Li HX, et al. ((2008)) Interaction between CD147 and P-glycoprotein and their regulation by ubiquitination in breast cancer cells. Chemotherapy 54:: 291--301.
38. Miletti-Gonzalez KE, Chen S, Muthukumaran N, Saglimbeni GN, Wu X, et al. ((2005)) The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 65:: 6660--6667.
39. Slomiany MG, Dai L, Bomar PA, Knackstedt TJ, Kranc DA, et al. ((2009)) Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res 69:: 4992--4998.
40. Gatenby RA, Gillies RJ, ((2004)) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:: 891--899.
41. Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, Pinheiro C, Silva J, et al. ((2011)) Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 11:: 312.
42. Rudrabhatla SR, Mahaffey CL, Mummert ME, ((2006)) Tumor microenvironment modulates hyaluronan expression: the lactate effect. J Invest Dermatol 126:: 1378--1387.
43. Kruh GD, Belinsky MG, ((2003)) The MRP family of drug efflux pumps. Oncogene 22:: 7537--7552.
44. Chen H, Wang L, Beretov J, Hao J, Xiao W, et al. ((2010)) Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin Exp Metastasis 27:: 557--569.
45. Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, et al. ((2011)) Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 104:: 707--713.
46. Schneiderhan W, Scheler M, Holzmann KH, Marx M, Gschwend JE, et al. ((2009)) CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut 58:: 1391--1398.
47. Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, et al. ((2011)) Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci 102:: 1007--1013.
48. Ma JJ, Chen BL, Xin XY, ((2009)) Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Arch Gynecol Obstet 279:: 149--157.
49. Wang L, Wu G, Yu L, Yuan J, Fang F, et al. ((2006)) Inhibition of CD147 expression reduces tumor cell invasion in human prostate cancer cell line via RNA interference. Cancer Biol Ther 5:: 608--614.
50. Zhu H, Zhao J, Zhu B, Collazo J, Gal J, et al. ((2012)) EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer. Prostate 72:: 72--81.
51. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, et al. ((2007)) Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 12:: 1424--1432.
52. Wegiel B, Jiborn T, Abrahamson M, Helczynski L, Otterbein L, et al. ((2009)) Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS One 4:: e7953.
53. Lee JT Jr, Steelman LS, McCubrey JA, ((2004)) Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64:: 8397--8404.
54. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, et al. ((2006)) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:: 249--279.
55. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, et al. ((2009)) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 106:: 268--273.
56. Ware JL, Paulson DF, Mickey GH, Webb KS, ((1982)) Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. J Urol 128:: 1064--1067.
57. Mesiano S, Ferrara N, Jaffe RB, ((1998)) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153:: 1249--1256.
58. Nishida N, Yano H, Komai K, Nishida T, Kamura T, et al. ((2004)) Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 101:: 364--1374.
59. Bougatef F, Quemener C, Kellouche S, Naimi B, Podgorniak MP, et al. ((2009)) EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood 114:: 5547--5556.
60. Ide H, Kikuchi E, Kono H, Nagata H, Miyajima A, et al. ((2010)) Docetaxel in combination with prednisolone for hormone refractory prostate cancer. Jpn J Clin Oncol 40:: 79--84.
61. Mollinedo F, Gajate C, ((2003)) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8:: 413--450.
62. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, et al. ((1995)) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81:: 801--809.